Evidence map›Paper›PMID 40642065›Full record

ArticleFrontiers in immunology2025

A consensus mathematical model of vaccine-induced antibody dynamics for multiple vaccine platforms and pathogens.

Kristen M Wilding, Carmen Molina-París, Jessica Z Kubicek-Sutherland, Benjamin McMahon, Alan S Perelson, Ruy M Ribeiro

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kristen M WildingTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States.
Carmen Molina-ParísTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States.
Jessica Z Kubicek-SutherlandPhysical Chemistry and Applied Spectroscopy Group, Los Alamos National Laboratory, Los Alamos, NM, United States.
Benjamin McMahonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States.
Alan S PerelsonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States.
Ruy M RibeiroTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Vaccine platforms used in successful, licensed vaccines have varied among pathogens. However, antibody level is still the main clinical correlate of protection in most approved vaccines. Decisions as to the best vaccine platform to pursue for a given pathogen may be informed through improved understanding of the process of antibody generation and its temporal dynamics, as well as the relationship between these processes and the type of vaccine. Methods: We have analyzed the dynamics of antibody generation for different vaccine platforms against diverse pathogens, and developed a consensus mathematical model that captures antibody dynamics across these diverse systems. Initially, the model was fitted to a rich dataset of antibody and immune cell concentrations in a SARS-CoV-2 vaccine experiment. We then used concepts from machine learning, such as transfer learning, to apply the same model to a variety of systems, involving different pathogens, vaccine platforms, and booster dose use/timing, fixing most parameter values relating to the dynamics of the immune system. Results: The model includes B cell proliferation and differentiation, as well as the generation of plasma cells, which secrete large amounts of antibody, and memory B cells. Overall, the model describes antibody generation in all systems tested well and shows that the main differences across platforms are related to the dynamics of antigen presentation. Discussion: This model can be used to predict antibody generation in pairs of vaccine platform/pathogen, allowing for the use of in silico results to narrow down experimental burden in vaccine development.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesModels, ImmunologicalModels, TheoreticalSARS-CoV-2AnimalsB-LymphocytesHumansAntibodies, ViralCOVID-19 Vaccinesantibody dynamicsB cellebolamathematical modelmemorySARS-CoV-2vaccinevaccine platform

Identifiers

PMID40642065
PMCPMC12241011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.